Diabetes & Endocrine System

TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes

Primary disease category: 

The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10 to below 18 years and are currently taking metformin, insulin or both drugs (DINAMO TM) or who are treatment naïve or not on active treatment after metformin withdrawal (DINAMO TM MONO) .

Primary disease category: 

The molecular nature of insulin resistance in human muscle is still incompletely defined. For almost thirty years we have been trying to understand the mechanisms that explain why muscle in patients who are obese or have type 2 diabetes only poorly uses fat for fuel. We termed this metabolic inflexibility. This causes fat to build up in muscle and other tissues, and causes the patient to respond poorly to insulin. We now think there are two proteins, called ANT1 and VWA8, that might be responsible for at least part of this.

Primary disease category: 
Secondary disease category(ies): 

People who are obese or who have type 2 diabetes are insulin resistant. Insulin resistance is when the body does not use insulin correctly, and more insulin is needed to keep blood sugar levels normal. In this study we are trying to better understand the causes of insulin resistance.  People with insulin resistance have mitochondria that do not work well in muscle. Mitochondria are tiny parts of cells responsible for making energy, and we will be looking at these to see how they are involved in insulin resistance.

Primary disease category: 
Secondary disease category(ies): 

Phase 3 study will look at a population of diabetic foot ulcer patients having adequate perfusion, with 
or without neuropathy, and a high suspicion of associated osteomyelitis in a complex high grade wound. The study will look at the application of human placental umbilical cord tissue to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing omplete healing within 25 weeks of initiating therapy, compared with 
standard care alone. 

Primary disease category: 

Researchers want to find out more about a device called PriMatrix® Dermal Repair Scaffold. PriMatrix is an
approved device for treatment of diabetic foot ulcers as well as other medical problems.
The main purpose of this study is to see if PriMatrix® Dermal Repair Scaffold is effective in the management of
diabetic foot ulcers in subjects with diabetes and without significantly decreased blood flow. In addition, safety
will be evaluated.

Primary disease category: 
Secondary disease category(ies): 

A team at the U of A and Banner Health is looking for people who have been diagnosed with Type 2 diabetes to join a study about a new approach to managing your blood sugar.

The study will last about 1 month and will take place at a UA/Banner Health outpatient clinic near BUMC-Tucson South. You will attend an individual education session and receive information that might help you lose weight.

Primary disease category: 
Secondary disease category(ies): 

A research team at the U of A is looking for people who have been diagnosed with Type 2 diabetes to join a study about a new mobile application being designed to help people manage Type 2 diabetes.

We will ask you to review different ways to track your diet and give us your opinions about them. If you join the study, you will attend a one-time in-person visit with the researchers at a UA facility near BUMC South.

The visit will last for about an hour.

Primary disease category: 
Secondary disease category(ies): 

phase III, randomized, double-blind, placebo-controlled, multicenter, 7-month study designed to assess the safety and efficacy of intramuscular (IM) injections in the calf of VM202 in patients with chronic nonhealing foot ulcers. Three hundred patients will be randomized in a 2:1 ratio of VM202 or placebo injections:

Active -VM202 + standard of care - 200 patients
Control - Placebo (VM202 Vehicle) + standard of care - 100 patients

Primary disease category: 

We are looking for families with a child or adolescent with a diagnosis of type 1 diabetes to participate in a study examining the effects of an intervention to assist families with their daily routines. Assessments and the intervention consultation address sleep, school, and family activities that may help or interfere with diabetes management.

Primary disease category: 
Secondary disease category(ies): 

Pages

Subscribe to RSS - Diabetes & Endocrine System